Pure Global AI
NCT06339216Not yet recruiting

A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.

A Phase II Clinical Study of Adebrelimab Injection in Combination With Apatinib and Paclitaxel for Injection (Albumin-bound) as Second-line Therapy in Patients With Advanced Gastric Cancer Who Had Previously Received Immunotherapy.
Chinese PLA General HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chinese PLA General Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Mar 20, 2024
End date
Nov 30, 2026
Enrollment
30 participants
Primary outcome

ORR

Summary

Phase II Clinical Study of Adebrelimab Combined with Apatinib and Paclitaxel for
 Injection(Albumin Bound) as Second-line Therapy in Patients with Advanced Gastric Cancer
 Previously Treated with Immunotherapy

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06339216
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06339216 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chinese PLA General Hospital and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.